Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;56(7):408-417.
doi: 10.3928/23258160-20250228-01. Epub 2025 Apr 18.

Early Outcomes of Faricimab Treatment for Diabetic Macular Edema in Patients Previously Treated With Anti-VEGF Therapy

Nitesh Mohan, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma

Early Outcomes of Faricimab Treatment for Diabetic Macular Edema in Patients Previously Treated With Anti-VEGF Therapy

Nitesh Mohan et al. Ophthalmic Surg Lasers Imaging Retina. 2025 Jul.

Abstract

Background and objective: The aim of this study was to evaluate the short-term outcomes of switching to intravitreal faricimab injections (IFIs) from prior anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of diabetic macular edema (DME).

Patients and methods: A retrospective review was done of patients with DME previously treated with anti-VEGF and subsequently switched to IFIs. Optical coherence tomography scans were assessed qualitatively and quantitatively to evaluate intraretinal fluid changes and central subfield thickness (CST).

Results: A total of 62 eyes from 41 patients were analyzed with a mean follow-up time of 36.4 ± 14.4 weeks. After receiving three IFIs, treatment interval increased significantly by 3.2 weeks (P < 0.001), CST decreased significantly by 43.8 µm (P = 0.014), and visual acuity remained stable (63.2 vs 64.4 approximate ETDRS letters, P = 0.720). Seventeen eyes (27.4%) were switched back to their prior anti-VEGF agent, with one case of suspected IFI-related uveitis.

Conclusion: Faricimab appears to be a viable option for some DME patients who require a change in anti-VEGF therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:408-414.].

PubMed Disclaimer

Conflict of interest statement

Disclosure: AS is a consultant for Genentech/Roche and Apellis. KET has received grants from Genentech/Roche, Iveric Bio, Regeneron, and Zeiss; and is a consultant for Alimera, Apellis, Bausch, Eyepoint, Genentech/Roche, and RegenXBio. DAM is a consultant for Alimera Sciences and Bausch&Lomb. ASB has received a grant from Genentech. PKK is a consultant for Alcon, Alexion, Alkeus, Abbvie, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX, Astellas, Augen Therapeutics, Aviceda, Bayer, Bausch&Lomb, Beacon Therapeutics (AGTC), Biogen Idec, Bionic Vision Technologies, Carl Zeiss Meditec, Celltrion Healthcare Co., Complement Therapeutics, Galimedix, Innovent, Invirsa, iRenix, Isarna, Janssen, jCyte, Kanaph Therapeutics, Kanghong, Kera Therapeutics, Kriya Therapeutics, Nanoscope Therapeutics, Ocugenix, Ocuphire, Omeros, Osanni Bio, Panther Pharmaceuticals, Ray Therapeutics, RegenXBio, Resonance Medicine, RetinaAI Medical AG, Retinal Sciences, ReVana, Revopsis, Roivant, Samsung Bioepis, Sandoz, SGN Nanopharma, SmileBiotek Zhuhai, Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa, Tilak, Unity Biotechnology, Vanotech, and VisgenX; and is an employee of Ocular Therapeutix; and an equity owner of Ocular Therapeutix, Revopsis, AAVAntgarde Bio, Oculis, and Ocuphire. JPE has received grants from Genentech/Roche, Iveric Bio, Aerpio, Alcon, Allergan, Boehringer Ingelheim, Regeneron, Thrombogenics, and Novartis; is a consultant for Aerpio, Novartis, Zeiss, Alcon, Leica, Santen, Allergan, Genentech/Roche, Bausch, Regeneron, Adverum, Allegro, Thrombogenics, and Stealth; and holds patents with Leica. AR has received grants from AGTC, Genentech, and Apellis; is a consultant for AbbVie, Alcon, Zeiss, Genentech, Regeneron, Apellis, Iveric Bio, and Samsara Vision; and has received honoraria from Apellis, Regeneron, Genentech, and Iveric Bio. SKS has received grants from Allergan, Eyepoint, Novartis, and Regeneron; and is a consultant for AbbVie, Adverum, Allergan, Bausch, Eyepoint, iCyte, Novartis, and Zeiss. SS has received grants from Allergan, Genentech/Roche, Gilead, IONIS, and Santen; and is a consultant for AbbVie, Alimera, Apellis, Bausch, Clearside, Eyepoint, Iveric Bio, Genentech/Roche, RegenXBio, and Regeneron. The remaining authors have disclosed no potential conflicts of interest, financial or otherwise.

MeSH terms

LinkOut - more resources